Replies to post #244088 on Avid Bioservices Inc (CDMO)

[biopharm]

Janney Healthcare Analysts

Roy Buchanan, Ph.D.
Vice President, Biotechnology
212-940-6985

Debjit Chattopadhyay, Ph.D.
Managing Director, Biotechnology
215-665-6224

Paul Knight, CFA
Managing Director, Head of Healthcare Research
212-888-2696

Ken Trbovich, CFA
Director, Specialty Pharmaceuticals
215-665-6290

http://www.janney.com/institutions--corporations/equities/equity-research/our-team

.... looks like Cantor Fitzgerald's Mara Goldstein is fully aware of PS Targeting potential, as she shows up with George Z. and Joe Pantginis

https://www.linkedin.com/in/mara-goldstein-11503a11
http://www.thelifesciencesreport.com/pub/na/the-small-cap-biotech-watchlist-2015-unwrapped-who-are-these-guys-and-why-are-they-here

Chiara Russo (ex-Janney) shows up over at Cantor Fitzgerald as well

https://www.linkedin.com/in/chiara-russo-4a05165

just tossing some puzzle pieces out here.... guess I'm curious about the new top 3 increase by the time mid Feb 2016 comes along

We should have all 4 analysts, increasing price targets, within 30 days of the conference call

[biopharm]

Why does Janney all of a sudden have interest in two additional healthcare analysts and both happen to cover Peregrine Pharmaceuticals ? Coincidence ....? I do not believe so and I'd even take it as far as Janney was targeting those close to Peregrine and maybe they figure they get some inside scoop of whats to come by picking up Roy and Debjit

Many must know that I have followed Piper Jaffray closely ever since Charles Duncan came on board over there and just part of my last post above, shows how Roy (ex-Piper Jaffray and filled in even for Charles Duncan on some cc's..) arrives over at Janney...etc

but now, even more puzzling, is that Piper Jaffray drops coverage of Peregrine as of Dec 19, 2015 and brokers released the info earlier this evening Dec 23, 2015.

----------------

Piper Jaffray drops coverage for PEREGRINE PHARMACEUTICALS INC.
BY Investars Analyst Actions - public
— 7:07 PM ET 12/23/2015

On December 19, 2015 Piper Jaffray dropped coverage for PEREGRINE PHARMACEUTICALS INC. ( PPHM )

---------------

Amazing, I don't see PPHM on the list below now so maybe Sarah Weber can convince Charles Duncan and Piper Jaffray to get PPHM back into their coverage (unless Piper is upset with Peregrine for some reason now ?? )

Now...

Associates:
Sarah Weber
Research Analyst

Universe Coverage:
Healthcare: Emerging BioPharma

ACAD ACADIA Pharmaceuticals Inc.
AIMT Aimmune Therapeutics, Inc.
ADHD Alcobra Ltd
ALXA Alexza Pharmaceuticals, Inc.
ARGS Argos Therapeutics, Inc.
AXON Axovant Sciences Ltd.
BCRX BioCryst Pharmaceuticals, Inc.
CARA Cara Therapeutics Inc.
CPRX Catalyst Pharmaceuticals, Inc.
CLVS Clovis Oncology, Inc.
CLCD CoLucid Pharmaceuticals, Inc.
CORT Corcept Therapeutics Inc.
CTIC CTI BioPharma Corp.
CYTK Cytokinetics, Incorporated
GERN Geron Corporation
HALO Halozyme Therapeutics, Inc.
INO Inovio Pharmaceuticals, Inc.
MRTX Mirati Therapeutics, Inc.
NANO FP Nanobiotix SA
NBIX Neurocrine Biosciences Inc.
ONTX Onconova Therapeutics, Inc.
OREX Orexigen Therapeutics, Inc.
PTN Palatin Technologies, Inc.
SGMO Sangamo BioSciences, Inc.
THLD Threshold Pharmaceuticals, Inc.
UNIS Unilife Corporation
VBLT Vascular Biogenics Ltd.
VTVT vTv Therapeutics, Inc.
ZYNE Zynerba Pharmaceuticals, Inc.

http://www.piperjaffray.com/2col.aspx?id=7&analystid=1275&title=Analyst%20Information%20for%20Charles%20Duncan,%20PhD

Sarah Weber, you research in the past at Boston Childrens Hospital included IBM (Inflammatory Bowel Disease) and if you dig deep enough ---> you will find out that increased %'s of flipped PS correlates there as well to negative outcomes...and maybe even infliximab targets flipped PS!

Ok Sarah, further below are a couple links to get you on the correct trail (..much research proves flipped PS is everywhere) and I don't want you to outshine Charles Duncan over there at Piper Jaffray's since you've only been there 9 months, but the facts are the facts and why in the world would Piper Jaffray drop coverage of Peregrine Pharmaceuticals ??

https://www.linkedin.com/in/sarah-weber-05a31061

Amgen and Johnson/Johnson are clients to her prior employer= Marketing Evolution ( I know... sometimes I dig deeper and no clues but one must look under every rock just in case )

http://www.marketingevolution.com/about/clients/



--------------------------

Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases.
..
..
CONCLUSIONS:

Higher concentrations of aPS/PT IgG and IgM were found in IBD patients at the beginning of the biological treatment period compared to the maintenance treatment period. Moreover, aPS/PT IgG were more frequent in ATI-positive individuals, which was not observed in aPL. We speculate that there is a relationship between the aPS/PT and the severity of inflammation and auto-aggressive processes in IBD.

http://www.ncbi.nlm.nih.gov/pubmed/26000139

-------------------------

Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease

2015
..
..
..

Summary

Inflammatory bowel disease (IBD)-associated thromboembolic event often lacks precise aetiology. The aim of this study was to investigate the contribution of phosphatidylserine (PS) exposure and neutrophil extracellular traps (NETs) towards the hypercoagulable state in IBD. We demonstrated that the levels of PS exposed MPs and the sources of MP-origin, platelets, erythrocytes, leukocytes and cultured endothelial cells (ECs) were higher in IBD groups than in healthy controls using flow cytometry and confocal microscopy.
..
..
http://th.schattauer.de/en/contents/archive/issue/special/manuscript/25350.html

----------------------------------------------------